LAG3 and non-small cell lung carcinoma: A cross-indication biomarker analysis is underway to compare the immune microenvironments of responsive and non-responsive tumors (for example, melanoma versus NSCLC/ESCC), with the aim of elucidating determinants of heterogeneity in patient response to dual PD-1/LAG-3 blockade.